Aardvark Therapeutics, Inc. Common Stock (AARD) Stock
NASDAQ · AARD
5.57
Fundamentals
Market cap
$117.74M
Price / Earnings ratio
-1.7x
Price / Sales ratio
N/A
Price / Book ratio
1.6x
Return on assets
-0.6%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
SectorHealthcare
IndustryBiotechnology
Employees28
CEODr. Tien-Li Lee M.D.
IPO DateFeb 13, 2025
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Tien-Li Lee M.D. | CEO, Secretary & Chairman | 1975 |
| Mr. Nelson B. Sun M.B.A. | CFO & COO | 1977 |
| Dr. Manasi Sinha Jaiman M.D., M.P.H. | Chief Medical Officer | 1981 |
| Dr. Dvorit Samid Ph.D. | Executive Vice President of Medical Affairs | — |
| Dr. Zhenhuan Zheng Ph.D. | Chief Research Officer | — |
| Mr. Ron Lewis II, Ph.D. | VP & Head of CMC | — |
| Mr. Justin T. Stege Ph.D. | VP and Head of Project Management & Strategy | — |
| Mr. Derrick C. Li | Chief Business Officer | — |
| Dr. Bryan Jones Ph.D. | Chief Executive Officer of Ardia | 1964 |
Fundamentals
Valuation
Market cap$117.74M
Price-to-sales ratioN/A
Price-to-book value1.57
Price-earnings ratio-1.70
Return on Equity-62.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.21
Income Statement
Average volume141,297
EBITDA$-69.47M
1 year high (52w)$17.94
1 year low (52w)$3.35
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



